Literature DB >> 18766963

Primary mediastinal large B-cell lymphomas treated with dose-intensified CHOP alone or CHOP combined with radiotherapy.

Marcel Massoud1, Serge Koscielny, Simona Lapusan, Jacques Bosq, Vincent Ribrag.   

Abstract

We retrospectively reviewed 105 cases of primary mediastinal large B-cell lymphoma (PMLBL). Patients were treated with dose-intensified chemotherapy according to the GELA protocols without planned radiotherapy. Radiotherapy was delivered to patients with a lymphoma proven sensitive to CHOP who could receive irradiation for localised disease. Seventy-six patients achieved a complete remission (24%) or unconfirmed CR (49%), and 15 (14%), a partial remission. Patients treated with intensified induction therapy had a better FFP rate than patients treated with CHOP chemotherapy even when radiotherapy was restricted to partial responders to the dose-intensified chemotherapy regimen (p = 0.01). In the multivariate analysis for overall survival, a poor performance status and CHOP chemotherapy remained associated with a poor outcome (p = 0.02 and 0.02, respectively). Radiotherapy might not be necessary in PMLBL when a CR or a Cru is achieved with dose-intensified chemotherapy. CHOP chemotherapy yield inferior results compared to dose-intensified chemotherapy with more frequent progression on therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18766963     DOI: 10.1080/10428190802203788

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  6 in total

1.  Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care.

Authors:  Theodoros P Vassilakopoulos; Gerassimos A Pangalis; Andreas Katsigiannis; Sotirios G Papageorgiou; Nikos Constantinou; Evangelos Terpos; Alexandra Zorbala; Effimia Vrakidou; Panagiotis Repoussis; Christos Poziopoulos; Zacharoula Galani; Maria N Dimopoulou; Stella I Kokoris; Sotirios Sachanas; Christina Kalpadakis; Evagelia M Dimitriadou; Marina P Siakantaris; Marie-Christine Kyrtsonis; John Dervenoulas; Meletios A Dimopoulos; John Meletis; Paraskevi Roussou; Panayiotis Panayiotidis; Photis Beris; Maria K Angelopoulou
Journal:  Oncologist       Date:  2012-01-26

2.  Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies.

Authors:  Theodoros P Vassilakopoulos; Sotirios G Papageorgiou; Maria K Angelopoulou; Sophia Chatziioannou; Vassilios Prassopoulos; Stamatios Karakatsanis; Maria Arapaki; Zois Mellios; Sotirios Sachanas; Christina Kalpadakis; Eirini Katodritou; Theoni Leonidopoulou; Ioannis Kotsianidis; Eleftheria Hatzimichael; Maria Kotsopoulou; Maria Dimou; Eleni Variamis; Dimitrios Boutsis; Evangelos Terpos; Evridiki Michali; George Karianakis; Pantelis Tsirkinidis; Chryssa Vadikolia; Christos Poziopoulos; Anna Pigaditou; Effimia Vrakidou; Marina P Siakantaris; Marie-Christine Kyrtsonis; Argyris Symeonidis; Konstantinos Anargyrou; Maria Papaioannou; Evdoxia Chatziharissi; Elissavet Vervessou; Maria Tsirogianni; Maria Palassopoulou; Gabriella Gainaru; Catherine Mainta; Panagiotis Tsirigotis; Theodora Assimakopoulou; Pavlina Konstantinidou; Helen Papadaki; Meletios-Athanassios Dimopoulos; Vassiliki Pappa; Themis Karmiris; Paraskevi Roussou; Ioannis Datseris; Panayiotis Panayiotidis; Kostas Konstantopoulos; Gerassimos A Pangalis; Phivi Rondogianni
Journal:  Ann Hematol       Date:  2021-02-01       Impact factor: 3.673

3.  Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma.

Authors:  Julien Lazarovici; Marie Terroir; Julia Arfi-Rouche; Jean-Marie Michot; Sacha Mussot; Valentina Florea; Maria-Rosa Ghigna; Peggy Dartigues; Cynthia Petrovanu; Alina Danu; Christophe Fermé; Vincent Ribrag; David Ghez
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-21       Impact factor: 9.236

4.  Role of radiotherapy in the treatment of primary mediastinal large B-cell lymphoma.

Authors:  Jingjing Wang; Xianling Liu; Fang Ma; Ming Huang; Yashpal Singh Kallychurn; Chunhong Hu
Journal:  Oncol Lett       Date:  2015-09-15       Impact factor: 2.967

5.  Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study.

Authors:  Vincent Camus; Cédric Rossi; Pierre Sesques; Justine Lequesne; David Tonnelet; Corinne Haioun; Eric Durot; Alexandre Willaume; Martin Gauthier; Marie-Pierre Moles-Moreau; Chloé Antier; Julien Lazarovici; Hélène Monjanel; Sophie Bernard; Magalie Tardy; Caroline Besson; Laure Lebras; Sylvain Choquet; Katell Le Du; Christophe Bonnet; Sarah Bailly; Ghandi Damaj; Kamel Laribi; Hervé Maisonneuve; Roch Houot; Adrien Chauchet; Fabrice Jardin; Alexandra Traverse-Glehen; Pierre Decazes; Stéphanie Becker; Alina Berriolo-Riedinger; Hervé Tilly
Journal:  Blood Adv       Date:  2021-10-12

6.  Primary mediastinal large B-cell lymphoma.

Authors:  Anna Dabrowska-Iwanicka; Jan A Walewski
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.